Global In Situ Hybridization (ISH) Market 2020-2024 | Evolving Opportunities with Abbott

ELMHURST, Ill. - July 22, 2020 - PRLog -- The in situ hybridization (ISH) market is poised to grow by USD 346.61 million during 2020-2024, progressing at a CAGR of about 7% during the forecast period.

The market is driven by the increasing demand for companion diagnostic tests. In addition, the national initiatives across the globe spurring molecular research activities are anticipated to boost the growth of the in situ hybridization (ISH) market.

A companion diagnostic test is a chemical examination performed on a sample that validates the use of a corresponding therapeutic product on the patient or a group of patients it is intended for. Regulatory organizations across the globe have made it mandatory to include information about the companion diagnostic test on the label of the corresponding therapeutic drug and on the package of the testing device itself. Oncology is the field where fluorescent in situ hybridization has been extensively used for companion diagnostics. Currently, some of the key drugs in oncology are available in the market with a companion diagnostic test, which uses the FISH technique. Apart from the approved tests, a few prominent tests are in the clinical pipeline from key vendors such as Abbott and F. Hoffmann-La Roche. Thus, the increasing demand for companion diagnostic tests is expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
View market snapshot before purchasing - https://www.technavio.com/report/in-situ-hybridization-ma...

Major Five In Situ Hybridization (ISH) Market Companies:

Bio-Rad Laboratories Inc.
Bio-Rad Laboratories Inc. is headquartered in the US and operates under various business segments, namely Life Science and Clinical Diagnostics. The company offers FISH and CISH products for clinical development.
Bio-Techne Corp.
Bio-Techne Corp. is headquartered in the US and offers products through the following business segments: Protein Sciences and Diagnostics and Genomics. The company offers RNA assays for clinical development of cancer related issues.
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. is headquartered in Switzerland and offers products through the following business segments: Pharmaceuticals and Diagnostics. The company offers ISH iVIEW Blue Plus Detection Kit, ultraView SISH DNP Detection Kit, ultraView Red ISH DIG Detection Kit, and ultraVIEW SISH Detection Kit.
Request free sample pages - https://www.technavio.com/talk-to-us?report=IRTNTR40880&a...